I5885
Monoclonal Anti-Human IgG (γ-chain specific) antibody produced in mouse
clone GG-5, ascites fluid
Synonym(s):
Monoclonal Anti-Human IgG (γ-chain specific)
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.46
Recommended Products
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
secondary antibodies
clone
GG-5, monoclonal
contains
15 mM sodium azide
technique(s)
indirect ELISA: 1:20,000
isotype
IgG1
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
Binds human IgG; does not bind other human Igs.The antibody is specific for a determinant on the heavy chain of human IgG. This antibody will form antigen-antibody complexes in the liquid phase in the presence of 3% PEG 6000.
Monoclonal Anti-Human IgG (mouse IgG1 isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Immunoglobulin G (IgG) belongs to the immunoglobulin family and is a widely expressed serum antibody. Immunoglobulins have two heavy chains and two light chains connected by a disulfide bond. It is a glycoprotein. IgG is usually found as a monomer. IgG is further subdivided into four classes namely, IgG1, IgG2, IgG3, and IgG4. About 70 percent of the total immunoglobulin consists of IgG.
Application
Elisa assays were performed using alkaline phosphatase conjugated monoclonal mouse anti-human IgG to detect antibodies against various S. Aureus antigens in the serum from healthy individuals. The antibody was diluted 1:30000 in PBSt and incubated with samples for 2 hours at 37 degrees. Reactin was developed using p-nitrophenyl phosphate substrate (Sigma).
Monoclonal Anti-Human IgG (γ-chain specific) antibody produced in mouse has been used in enzyme linked immunosorbent assay (ELISA).
Biochem/physiol Actions
Immunoglobulin G (IgG) mainly helps in immune defense. IgG participates in hypersensitivity type II and type III.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Alain Townsend et al.
Nature communications, 12(1), 1951-1951 (2021-03-31)
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these
Utility of the P 19 suppressor of gene-silencing protein for production of therapeutic antibodies in N icotiana expression hosts
Garabagi F, et al.
Plant Biotechnology Journal, 10(9), 1118-1128 (2012)
Charles Pilette et al.
Immunology and cell biology, 88(4), 486-493 (2010-01-20)
As previously reported by others for immunoglobulin (Ig)G, we observed that IgA can induce interleukin (IL)-10 expression in human monocytes. In this study, we explored the molecular mechanisms of IL-10 induction by IgA in monocytes and monocyte-derived dendritic cells (MD-DCs).
Freydoun Garabagi et al.
Plant biotechnology journal, 10(9), 1118-1128 (2012-09-19)
To study how the P19 suppressor of gene-silencing protein can be used effectively for the production of therapeutic glycoproteins, the following factors were examined: the genetic elements used for expressing recombinant proteins; the effect of different P19 concentrations; compatibility of
N Ruijne et al.
Clinical and vaccine immunology : CVI, 13(7), 797-801 (2006-07-11)
Vaccine trials with infants enrolled between 6 and 10 weeks of age (young infants) and 6 and 8 months of age (older infants) provided an opportunity to evaluate immunoglobulin G (IgG) isotype distribution and avidity maturation as indicators of antibody
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service